Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load

Hepatology Research

Volumn 25, Issue 4, 2003, Pages 364-370

  Arase, Yasuji ^a   Ikeda, Kenji ^a   Tsubota, Akihito ^a   Suzuki, Yoshiyuki ^a   Saitoh, Satoshi ^a   Kobayashi, Masahiro ^a   Akuta, Norio ^a   Someya, Takashi ^a   Kobayashi, Mariko ^a   Suzuki, Fumitaka ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; HCV RNA; Prolonged interferon treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; VIRUS RNA;

ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; GENOTYPE; HEARING IMPAIRMENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; JAPAN; LIVER BIOPSY; LYMPHOMA; MENTAL DISEASE; PATIENT ATTITUDE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

EID: 0037398202     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00327-3     Document Type: Article

References (25)

1. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994;19:1088-94.
2. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992;16:293-9.
3. Hagiwara H, Hayashi N, Mita E, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α. Hepatology 1992;15:37-41.
4. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind placebo-controlled trial. N Engl J Med 1998;321:1506-10.
5. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
6. Chayama K, Saitoh S, Arase Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991;13:1040-3.
7. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 1995;96:224-30.
8. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81.
9. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995;21:291-7.
10. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
11. Reichard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α 2b for 60 weeks. Hepatology 1994;19:280-5.
12. Saracco G, Borghesio E, Mesina P, et al. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon α-2b for chronic hepatitis type C. J Hepatol 1997;27:56-62.
13. Detmer J, Lagier R, Flynn J, et al. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV-genotypes by using branched-DNA technology. J Clin Microbiol 1996;34:901-7.
14. Garson JA, Tedder RS, Briggs M, et al. Detection of hepatitis C viral sequences in blood donations by 'nested' polymerase chain reaction and predictor of infectivity. Lancet 1990;335:1419-22.
15. Hashimoto M, Chayama K, Tsubota A, et al. Typing six major hepatitis C virus genotypes by polymerase chain reaction using primers derived from nucleotide sequences of the NS5 region. Int Hepatol Commun 1996;4:263-7.
16. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
17. Dusheiko G, Schmilovitzs-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994;19:13-8.
18. The International HCV Collaborative Study Group, Mellor J, Holmes EC, Jarivis LM, Yap PL, Simmonds P. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. J Gen Virol 1995;76:2423-507.
19. Arase Y, Ikeda K, Chayama K, et al. Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C. J Gastroenterol 2000;35:221-5.
20. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317-23.
21. Arase Y, Kumada H, Chayama K, et al. Interferon retreatment of nonresponders with HCV-RNA positive chronic hepatitis C. J Gastroenterol 1994;29:299-304.
22. Toyoda H, Nakano S, Takeda I, et al. Retreatment of chronic hepatitis C with interferon. Am J Gastroenterol 1994;89:1453-9.
23. Arase Y, Kumada H, Chayama K, et al. Usefulness of HCV-RNA counts by the method of HCV-bDNA probe in interferon retreatment for patients with HCV-RNA positive chronic hepatitis C. Int Hepatol Commun 1995;4:19-25.
24. Chemello L, Cavalletto L, Donada C, et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997;113:1654-9.
25. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2 alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.